Impact of residual disease biomarkers on the prognosis of HER2‐positive breast cancer following neoadjuvant therapy

BACKGROUND: The changes in prognostic factors and clinicopathological characteristics of residual disease following neoadjuvant therapy (NAT) for breast cancer are important references for postoperative adjuvant therapy. The analyses of the relationship between the clinicopathological characteristic...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Youzhao, Zhu, Mingda, Lv, Minhao, Yuan, Peng, Chen, Xiuchun, Liu, Zhenzhen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10242303/
https://www.ncbi.nlm.nih.gov/pubmed/36951436
http://dx.doi.org/10.1002/cam4.5839

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10242303/
https://www.ncbi.nlm.nih.gov/pubmed/36951436
http://dx.doi.org/10.1002/cam4.5839

Ejemplares similares